The BioProcess Insider Expression Platform

Snippets from BIO 22: Fujifilm Diosynth’s Martin Meeson

In the first of my series of interviews from BIO 2022 in San Diego, I speak with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, one of the most prominent contract development and manufacturing organizations (CDMOs).

He talks about the CDMO's part in battling COVID-19, the major capital expenditure projects underway at facilities in Denmark, North Carolina, and elsewhere, and Fujifilm's presence in the advanced therapies space, and why it has chosen to invest in mRNA, gene therapies, and allogeneic -- but not autologous -- cell therapy capabilities.

 

Opening the gates for women in biotech, with Nadine Ritter

There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential.

“Career development is an integral part of DEI because it’s diversity inclusion at the starting gate,” rather than just a tick-box exercise among the C-suite, said Nadine Ritter, president and analytical advisor at Global Biotech Experts at a DEI coffee morning at BPI Europe in Vienna. “It will never really change at the top unless we remediate the gates [below].”

This podcast is the full conversation with BioProcess Insider reporter Millie Nelson 

The changing dynamics between drug sponsors and their CDMO partners

Over the past decade, the relationships drug developers have with their third-party biomanufacturers has evolved from relatively simple transactional services to integrated and complex strategic partnerships.

This podcast replays a panel discussion from EBD's BIO EUROPE Spring event where editor Dan Stanton discusses the changing way pharma works with CDMOs with delegates from Samsung Biologics, Catalent, and AGC Biologics.

Topics covered include: The history of CDMOs, M&A within the industry, the advent of new modalities and, of course, the COVID-19 pandemic.

Dendreon‘s leap into the cell therapy CDMO space

Dendreon, a pioneer in the cell therapy space through its commercial product Provenge, has relaunched itself as a contract development and manufacturing organization (CDMO).

BioProcess Insider speaks with Maria Cho, the VP of Business Development and Corporate Strategy, about Dendreon's strategic growth efforts in the cellular immunotherapy space and how it is embracing its proven success in the field to support others.

GSK's Digital Twin Approach to Vaccine Development, with Matt Harrison

A digital twin is a virtual representation that serves as the real-time digital counterpart of a physical object or process. Biopharma giant GlaxoSmithKline (GSK) has adopted this technology to advance its vaccine development and manufacturing division.

A year after partnering with Siemens and Atos to pilot a digital twin in order to create a real-time simulation of the entire vaccine manufacturing process, we sat down (virtually, sadly) with Matt Harrison, head of Sciences, Digital Innovation and Business Strategy at GSK to discuss the current status of this project.

 

Keep up with BioProcess Insider on our website.

Follow us on LinkedIn and Twitter:

• @BioProInsider
• @BioProcessIntl
• @Dan5tanton

On Board the Cell Shuttle with Cellares' Fabian Gerlinghaus

Having raised $82 million in its latest funding round, tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.

 

We spoke with co-founder and CEO Fabian Gerlinghaus about the current limitations in CAR-T production and how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space

 

Keep up with BioProcess Insider on our website.

Follow us on LinkedIn and Twitter:

• @BioProInsider
• @BioProcessIntl
• @Dan5tanton

 

The Future of Cell and Gene Therapies, with E&Y’s Adlai Goldberg

The cell and gene therapy sector is on the cusp of flourishing in the vast pharma landscape. Money is flowing in, manufacturing challenges are being overcome, people are actually being treated and cured. Even COVID-19 may be seen as a driving force for the burgeoning sector. But what does the future hold? Ernst & Young’s Adlai Goldberg describes the steps industry must take to advance the advanced therapy space and how it must move to balance the individualized autologous approach with more sustainable allogeneic products.

 

Keep up with BioProcess Insider on our website.

 

Follow us on LinkedIn and Twitter:

• @BioProInsider
• @BioProcessIntl
• @Dan5tanton

Fill & Finish in the time of COVID, with Vinenza Pironti

Vincenza Pironti - Global SME, Steriles, ThermoFisher Scientific - sits down (at a distance) with editor Dan Stanton to discuss aseptic manufacturing in the current climate and how vaccine and biologic makers can ensure a robust, global fill/finish supply both during the COVID pandemic and beyond

Content is King in bioprocessing and beyond, with Brian Caine

After a quarter of a century in the life sciences publishing space, Brian Caine stepped down from his position as publisher of BioProcess International last year. He has played a huge part in the evolution of the trade media and still has his finger on the pulse of the bioprocess space. Here he discusses candidly how content marketing can make or break both advertisers and publications.

From mAbs to cell and gene therapies with Patrick Lucy

Having just been appointed chief operating officer of contract manufacturing services organization (MSA) Lykan Bioscience, Patrick Lucy reflects on an illustrious career in the biopharma space and the parallels of today's cell and gene therapy landscape with that of monoclonal antibodies 30 years ago.